Literature DB >> 36076000

Myasthenia gravis treated in the neurology intensive care unit: a 14-year single-centre experience.

Mirjana Zdraljevic1, Stojan Peric1,2, Marta Jeremic1, Dragana Lavrnic1,2, Ivana Basta1,2, Ljiljana Hajdukovic3, Dejana R Jovanovic1,2, Ivana Berisavac4,5.   

Abstract

INTRODUCTION: Severe myasthenia gravis (MG) exacerbation with respiratory failure and/or dysphagia usually requires monitoring and treatment in the neurology intensive care unit (NICU). The aim of our study was to identify all patients with severe MG exacerbation treated in the NICU in order to assessed potential factors affecting patients' need for mechanical ventilation, occurrence of complications and the final outcome.
METHODS: We retrospectively included all patients with severe exacerbation of MG who required management in the NICU during a 14-year period. Baseline sociodemographic and clinical features, data on medication, comorbidities and outcome were obtained by reviewing medical records and institutional databases.
RESULTS: Our study comprised 130 severe MG exacerbations detected in 118 patients. Median age of patients was 61.5 years, and women accounted for 58.5% of the patients. Half of the patients required mechanical ventilation during hospitalization. Lethal outcome was observed in 12.3% of severe MG exacerbations. Only elder age was an independent negative predictor of survival (OR 0.89, 95% CI 0.82-0.97, p < 0.01). Complications during hospitalization were detected in 50% of patients. A higher number of comorbidities (OR 1.09, 95% CI 1.60-2.35, p = 0.01) and mechanical ventilation (OR 28.48, 95% CI 8.56-94.81, p < 0.01) were independent predictors of complications during hospitalization.
CONCLUSION: Patients with a severe MG exacerbation who do not require mechanical ventilation have a good outcome after treatment in the NICU. Elder age is an independent predictor of lethal outcome in patients with severe MG exacerbation. Mechanical ventilation and a higher number of comorbidities lead to more frequent complications.
© 2022. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  Exacerbation; Intensive care; Myasthenia gravis; Outcome; Predictors

Year:  2022        PMID: 36076000     DOI: 10.1007/s10072-022-06379-z

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  26 in total

1.  Myasthenic crisis.

Authors:  Linda C Wendell; Joshua M Levine
Journal:  Neurohospitalist       Date:  2011-01

2.  Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry.

Authors:  A Ramos-Fransi; R Rojas-García; S Segovia; C Márquez-Infante; J Pardo; J Coll-Cantí; I Jericó; I Illa
Journal:  Eur J Neurol       Date:  2015-04-06       Impact factor: 6.089

3.  The management and outcome of patients with myasthenia gravis treated acutely in a neurological intensive care unit.

Authors: 
Journal:  Eur J Neurol       Date:  1998-03       Impact factor: 6.089

Review 4.  Myasthenia gravis: subgroup classification and therapeutic strategies.

Authors:  Nils Erik Gilhus; Jan J Verschuuren
Journal:  Lancet Neurol       Date:  2015-10       Impact factor: 44.182

Review 5.  Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America.

Authors:  A Jaretzki; R J Barohn; R M Ernstoff; H J Kaminski; J C Keesey; A S Penn; D B Sanders
Journal:  Neurology       Date:  2000-07-12       Impact factor: 9.910

6.  Myasthenic Crisis.

Authors:  Jawad F. Kirmani; Abutaher M. Yahia; Adnan I. Qureshi
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

7.  Predictors of outcome of myasthenic crisis.

Authors:  J Kalita; A K Kohat; U K Misra
Journal:  Neurol Sci       Date:  2014-02-05       Impact factor: 3.307

8.  Epidemiological study of adult-onset myasthenia gravis in the area of Belgrade (Serbia) in the period 1979-2008.

Authors:  D Lavrnic; I Basta; V Rakocevic-Stojanovic; Z Stevic; S Peric; A Nikolic; I Marjanovic; T Pekmezovic
Journal:  Neuroepidemiology       Date:  2013-01-24       Impact factor: 3.282

9.  Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals.

Authors:  A Alshekhlee; J D Miles; B Katirji; D C Preston; H J Kaminski
Journal:  Neurology       Date:  2009-05-05       Impact factor: 9.910

10.  Myasthenia gravis--treatment of acute severe exacerbations in the intensive care unit results in a favourable long-term prognosis.

Authors:  J Spillane; N P Hirsch; D M Kullmann; C Taylor; R S Howard
Journal:  Eur J Neurol       Date:  2013-02-11       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.